Elacestrant

ESR1 mutations are present in up to 40% of ER+, HER2- advanced or metastatic breast cancers.ESR1 mutations are a known driver of resistance to standard endocrine therapy, and so far, have been difficult to treat.ORSERDU is the first…

ESR1 mutations are present in up to 40% of ER+, HER2- advanced or metastatic breast cancers.ESR1 mutations are a known driver of resistance to standard endocrine therapy, and so far, have been difficult to treat.ORSERDU is the first…

Carrick to execute Phase 2 clinical trial in patients with CDK4/6i resistant HR+, HER2- metastatic breast cancer DUBLIN and FLORENCE, Italy, Dec. 19, 2022 /PRNewswire/ -- Carrick Therapeutics, an oncology-focused biopharmaceutical…